QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:EXAI

Exscientia (EXAI) Stock Forecast, Price & News

$5.01
-0.16 (-3.09%)
(As of 09/25/2023 ET)
Compare
Today's Range
$4.95
$5.17
50-Day Range
$4.53
$8.90
52-Week Range
$4.09
$11.52
Volume
390,369 shs
Average Volume
422,791 shs
Market Capitalization
$605.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Exscientia MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
159.5% Upside
$13.00 Price Target
Short Interest
Bearish
1.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Exscientia in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.32) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

819th out of 961 stocks

Biological Products, Except Diagnostic Industry

131st out of 161 stocks


EXAI stock logo

About Exscientia (NASDAQ:EXAI) Stock

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Price History

EXAI Stock News Headlines

Exscientia PLC ADR
Exscientia (NASDAQ:EXAI) Sees Unusually-High Trading Volume
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Exscientia Plc
Exscientia Shares Surge On AI Collaboration: The Details
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Exscientia Plc (EXAI) Receives a Buy from Barclays
The Latest Analyst Ratings for Exscientia
Why Shares of Exscientia Jumped on Wednesday
See More Headlines
Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

EXAI Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EXAI
Fax
N/A
Employees
481
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+158.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-146,850,000.00
Net Margins
-685.82%
Pretax Margin
-810.00%

Debt

Sales & Book Value

Annual Sales
$32.90 million
Book Value
$4.82 per share

Miscellaneous

Free Float
N/A
Market Cap
$608.08 million
Optionable
Not Optionable
Beta
0.55
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Prof. Andrew L. Hopkins DPHIL (Age 50)
    FMEDSCI, FRSE FRSC, Founder, CEO & Exec. Director
    Comp: $682.34k
  • Mr. Ben R. Taylor (Age 46)
    CFO, Chief Strategy Officer & Exec. Director
    Comp: $478.29k
  • Dr. David Hallett Ph.D. (Age 52)
    Chief Scientific Officer
  • Dr. Garry Pairaudeau Ph.D. (Age 57)
    Advisor
  • Dr. Michael Krams M.D. (Age 62)
    Chief Quantitative Medicine Officer
  • Ms. Eileen Jennings-Brown
    Chief Information Officer
  • Mr. Dan Ireland
    VP of Legal & Company Sec.
  • Ms. Caroline Rowland
    Chief People Officer
  • Mr. Richard Law
    Chief Bus. Officer
  • Prof. Charlotte Deane M.B.E.
    Ph.D., Chief AI Officer













EXAI Stock - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings
or view top-rated stocks.

What is Exscientia's stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price objectives for Exscientia's stock. Their EXAI share price forecasts range from $12.00 to $14.00. On average, they expect the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price.
View analysts price targets for EXAI
or view top-rated stocks among Wall Street analysts.

How have EXAI shares performed in 2023?

Exscientia's stock was trading at $5.33 at the beginning of the year. Since then, EXAI shares have decreased by 5.6% and is now trading at $5.03.
View the best growth stocks for 2023 here
.

Are investors shorting Exscientia?

Exscientia saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,280,000 shares, an increase of 13.4% from the August 15th total of 2,010,000 shares. Based on an average trading volume of 339,000 shares, the days-to-cover ratio is presently 6.7 days. Approximately 2.0% of the shares of the company are sold short.
View Exscientia's Short Interest
.

When is Exscientia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our EXAI earnings forecast
.

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The business earned $3.80 million during the quarter, compared to analysts' expectations of $16.27 million. Exscientia had a negative net margin of 685.82% and a negative trailing twelve-month return on equity of 31.67%.

What ETFs hold Exscientia's stock?

ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Exscientia IPO?

(EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

What is Exscientia's stock symbol?

Exscientia trades on the NASDAQ under the ticker symbol "EXAI."

Who are Exscientia's major shareholders?

Exscientia's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.20%), Platinum Investment Management Ltd. (3.30%), Pivotal bioVenture Partners Investment Advisor LLC (0.64%), Woodline Partners LP (0.63%), BlackRock Inc. (0.57%) and Point72 Asset Management L.P. (0.48%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exscientia's stock price today?

One share of EXAI stock can currently be purchased for approximately $5.03.

How much money does Exscientia make?

Exscientia (NASDAQ:EXAI) has a market capitalization of $608.08 million and generates $32.90 million in revenue each year. The company earns $-146,850,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

How many employees does Exscientia have?

The company employs 481 workers across the globe.

How can I contact Exscientia?

The official website for the company is www.exscientia.ai. The company can be reached via phone at 44-0-18-6581-8941 or via email at investors@exscientia.ai.

This page (NASDAQ:EXAI) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -